Source: AllCells Blog

AllCells Blog Progressing Ex Vivo Gene Editing Innovations with High-Quality Leukopaks

Treating human disease at the genetic level, by replacing defective genes or adding new genes to enhance native functions, has been a long-standing goal, with the first attempts at gene [...]The post Progressing Ex Vivo Gene Editing Innovations with High-Quality Leukopaks appeared first on AllCells.

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Jay Tong's photo - Chairman & CEO of AllCells

Chairman & CEO

Jay Tong

CEO Approval Rating

84/100

Read more